Drug intelligence / Profile preview

MAGACIL

Development stage: Preclinical
Lead developer: Keshihua (Nanjing) Biotechnology
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

MAGACIL is an investigational T-cell receptor (TCR) engineered cell therapy developed by Keshihua (Nanjing) Biotechnology (also known as TCRx). The therapy is categorized as a gene and cell drug intended for the treatment of graft-versus-host disease (GvHD) and immune deficiency. While the specific molecular target for MAGACIL has not been publicly disclosed, the company's platform focuses on leveraging TCR-based technologies to address complex immune-related conditions and malignancies by modifying T cells to achieve therapeutic immune modulation or restoration.

Beyond the preview

Go deeper on MAGACIL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAGACIL.

Explore the full profile